The Manufacturers Life Insurance Company Buys 23,515 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

The Manufacturers Life Insurance Company boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 283,870 shares of the biopharmaceutical company's stock after purchasing an additional 23,515 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.22% of Halozyme Therapeutics worth $13,572,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $69,000. Finally, Parkside Financial Bank & Trust increased its stake in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the sale, the director now directly owns 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,697 shares of company stock valued at $1,276,552 over the last three months. Company insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HALO. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. HC Wainwright reiterated a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Benchmark reissued a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded down $1.24 on Tuesday, hitting $59.38. 2,486,600 shares of the stock were exchanged, compared to its average volume of 1,447,625. The firm's 50 day moving average is $60.88 and its two-hundred day moving average is $55.49. Halozyme Therapeutics, Inc. has a one year low of $40.87 and a one year high of $66.00. The firm has a market capitalization of $7.34 billion, a PE ratio of 17.31, a P/E/G ratio of 0.42 and a beta of 1.26. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.